ClinicalTrials.gg
RecruitingNCT06150664Updated Nov 4, 2026

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

A Phase 1 interventional study of CTX-8371 in Non Small Cell Lung Cancer, Triple Negative Breast Cancer and Hodgkin Lymphoma, sponsored by Compass Therapeutics. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Compass Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Nov 4, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
1,173rd of 3,001
85 · median 56
Started
2024
with 157 others
Phase 1
928 of 3,374
134 open now
Primary completion
2026-12
later than 240 of 893 live
Registered
2,950th of 3,374
by date

Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,173rd largest by planned enrollment of the 3,001 interventional ones that give a count, is one of 158 that started in 2024, is one of 928 in phase 1, reaches primary completion later than 240 of the 893 other live ones, and was the 2,950th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

Read the detailed description

This Phase 1, open-label, first-in-human study will evaluate the safety, tolerability, immunogenicity, and pharmacokinetic profile of CTX-8371 monotherapy. Preliminary anti-tumor activity of CTX-8371 will also be assessed. The study will be conducted in 2 cohorts: Dose escalation and Dose expansion. The Dose Escalation Cohort will utilize a 3+3 design to evaluate five dose levels (0.1-10.0 mg/kg) of CTX-8371 given as an IV infusion once every 2 weeks. Patients in the Dose Expansion Cohort will receive CTX-8371 as an IV infusion at 3.0 mg/kg or 10.0 mg/kg at a 1:1 allocation.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Triple Negative Breast Cancer
  • Hodgkin Lymphoma
  • Head and Neck Squamous Cell Carcinoma
  • Malignant Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older
  2. Patients must have a or cytologically confirmed diagnosis of locally advanced unresectable or disease that is to standard therapy or for which no effective standard therapy is available, including

    1. Malignant Melanoma (MM)

      • Patients who have progressed after a minimum of 2 doses of a /PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1/PD-L1 blocking antibody
      • Patients must have had prior testing for BRAF V600 mutations. Patients with BRAF V600 activating mutation must have received prior therapy with a BRAF/MEK inhibitor
      • Uveal and mucosal melanoma are excluded
    2. Head and Neck squamous cell carcinoma (HNSCC)

      • HNSCC of oral cavity, oropharynx, hypopharynx, or larynx
      • Patients who have progressed after a minimum of 2 doses of a PD-1/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1/PD-L1 blocking antibody
      • Patients must have received prior treatment with platinum-based chemotherapy
    3. Non-Small Cell Lung Cancer (NSCLC)

      • Patients who have progressed after a minimum of 2 doses of a PD-1/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1/PD-L1 blocking antibody
      • Patients must have received prior treatment with platinum-based chemotherapy
    4. Triple Negative Breast Cancer (TNBC)

      • ER/PR and status should be defined by ASCO/CAP guidelines (JCO Allison et al 2020)
      • Patients with HER2-low cancers (HER2 IHC 1+ or 2+/ISH negative) are excluded
      • Patients must have received prior sacituzumab govitecan and if PD-L1 ≥10% by CPS pembrolizumab with chemotherapy
    5. Classical Hodgkin Lymphoma (HL)

      • Patients must have received at least two prior systemic therapies including brentuximab vedotin (if eligible) and a prior PD-1 inhibitor
      • Patients must have experienced less than a CR (according to Lugano criteria) to anti- PD-1 treatment
    6. (Cohort 2 Dose Expansion): Non-Small Cell Lung Cancer (NSCLC)

      • Patients who have progressed after a minimum of 2 doses of a PD-1/PD-L1 treatment
      • Patients must have received prior treatment with platinum-based chemotherapy
    7. (Cohort 2 Dose Expansion) Triple Negative Breast Cancer (TNBC)

      • ER/PR and HER2 status should be defined by ASCO/CAP guidelines (JCO Allison et al 2020)
      • Patients must have received prior sacituzumab govitecan and if PD-L1 ≥10% by CPS pembrolizumab with chemotherapy
      • Patients with HER2-low tumors (HER2 IHC 1+ or 2+/ISH negative) need to have received fam-trastuzumab deruxtecan (Enhertu)
    8. (Cohort 2 Dose Expansion) Classical Hodgkin's Lymphoma (HL)

      • Patients must have received at least two prior systemic therapies including brentuximab vedotin (if eligible) and a prior PD-1 inhibitor.
      • Patients must have received at least 12 weeks of treatment with a PD-1/PD-L1 inhibitor as a monotherapy or in combination and had at least stable disease or progressive disease (PD) with overall clinical benefit.
  3. Patients with NSCLC, MM, TNBC, and HNSCC must have per 1.1. Patients with HL must have at least one measurable lesion > 1.5 cm for nodal, > 1.0 cm for extranodal FDG-avid disease by the Lugano (2014) response criteria. Tumor sites that are considered measurable must not have received prior radiation
  4. (ECOG) performance status 0-1
  5. Adequate bone marrow function defined by absolute neutrophil (ANC) of ≥ 1.5×109/L, count of ≥ 100.0×109/L, and of ≥ 9.0 g/dL (with or without transfusion)

    a. (Cohort 2 Dose Expansion) Adequate bone marrow function defined by absolute neutrophil (ANC) of ≥ 1.5×109/L, platelet count of ≥ 100.0×109/L, and hemoglobin of ≥ 9.0 g/dL (with or without transfusion) within 2 weeks from the first dose of CTX-8371.

    - Blood transfusion is not allowed within 2 weeks from the first dose of CTX-8371

  6. Adequate hepatic function defined as serum total ≤ 1.5 × , /ALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases)
  7. Adequate renal function defined as ≥ 30mL/min by Cockcroft-Gault equation
  8. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years or commits to use 2 acceptable forms of (defined as the use of an intrauterine device (IUD), a barrier method with spermicide, condoms, any form of hormonal contraceptives) or abstinence for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment
  9. Female patients who are women of (WOCBP) must have a negative serum pregnancy test at Screening within 7 days of dosing with CTX-8371
  10. Last dose of previous PD-1 or PD-L1 therapy ≥ 28 days, other anticancer therapy > 21 days (or 2 half-lives for proteins, whichever is longer), radiotherapy >21 days (concurrent localized palliative radiotherapy is allowed during CTX-8371 treatment), or surgical intervention >21 days prior to the first dose of CTX-8371
  11. Resolution of all prior anti-cancer therapy toxicities ≤ Grade 2
  12. ≥ 12 weeks
  13. Capable of understanding and complying with protocol requirements
  14. Signed and dated institutional review board (IRB)/independent ethics committee (IEC)-approved form (ICF) before any protocol-directed screening procedures are performed

Exclusion criteria

Exclusion Criteria:

  1. Developed adverse reaction to or PD-L1 therapy, including immune related adverse reactions, which led to discontinuation of treatment
  2. Systemic therapy with agents within 7 days before the start of CTX-8371 treatment. Topical, intranasal, intraocular, or inhaled and physiologic replacement for patients with adrenal insufficiency are allowed
  3. Patient is a pregnant or lactating
  4. Prior organ transplantation
  5. Patients with evidence of active virus (HBV), virus (HCV) or (HIV) infection. Patients with positive HBsAg and/or detectable HBV DNA are eligible only if adequately controlled on antiviral therapy according to institutional standards and liver function eligibility criteria are also met. HCV patients showing sustained viral response or patients with immunity to HBV infection may enroll.
  6. Active disease or medical conditions requiring chronic steroid (i.e., > 10 mg/day prednisone or equivalent) or immunosuppressive therapy. Patients with a prior history of autoimmune disease may be eligible following discussion with the Medical Monitor
  7. History of primary other than the malignancy under study will be excluded, except for malignancies with a negligible risk of or death (e.g., 5-year OS rate >90%). Prior malignancy history will be evaluated on a case-by-case basis by the Sponsor Medical Monitor.
  8. Symptomatic or uncontrolled central nervous system and or active . Patients with equivocal findings or with confirmed brain metastases are eligible for the study provided that they are asymptomatic and radiologically and neurologically stable without the need for corticosteroid treatment or seizure prophylaxis for ≥4 weeks before the first dose of study drug. Prior treatment with either surgery or radiation is permitted and all patients with a history of CNS or brain lesions require imaging during screening to confirm stability.
  9. Other medical condition that in the opinion of the Investigator and/or Sponsor Medical Monitor may interfere with the conduct and/or interpretation of the current study, including:

    • Congestive heart failure (> Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or clinically significant cardiac arrhythmias
    • (using Fridericia correction calculation) > 480 msec
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Cohort 1

    Escalating doses of CTX-8371

    Drug: CTX-8371

  • Experimental
    Dose Expansion Cohort 2

    Two CTX-8371 dose groups (3.0 mg/kg and 10.0 mg/kg) in three tumor type subgroups (NSCLC, TNBC, and HL)

    Drug: CTX-8371

Interventions

  • DrugCTX-8371

    Intravenous (IV) infusion every two weeks.

06

What researchers measure

Primary outcomes

  1. Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371

    Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-8371, average of 6 months

  2. Cohort 1: Determine the dose(s) of CTX-8371 to be further examined in Cohort 2 and Phase 2 studies

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks ) until 30 days after the last dose of CTX-8371 (average of 6 months )

  3. Cohort 2: Evaluate the safety and tolerability of CTX-8371 at 3.0 mg/kg and 10.0 mg/kg

    Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-8371 (up to 2 years)

Secondary outcomes

  1. Cohort 1 and 2: Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Time frame: Baseline until confirmed disease progression (up to 2 years)

  2. Cohort 1 and 2: Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Time frame: From the date of first confirmed CR or PR until the first date of recurrent or progressive disease (up to 2 years)

  3. Cohort 1 and 2: Progression-Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Time frame: From first dose of CTX-8371(Cycle 1 Day 1,Cycle = 2 weeks ) until disease progression or death, whichever occur first (up to 2 years)

  4. Cohort 1 and 2: Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Lugano (2014)

    Time frame: Baseline until confirmed disease progression (up to 2 years)

  5. Cohort 1 and 2: Duration of Response (DOR) as per Lugano (2014)

    Time frame: From the date of first confirmed CR or PR until the first date of recurrent or progressive disease (up to 2 years)

  6. Cohort 1 and 2: Progression-Free Survival (PFS) as per Lugano (2014)

    Time frame: From first dose of CTX-8371(Cycle 1 Day 1,Cycle = 2 weeks ) until disease progression or death, whichever occurs first

  7. Cohort 1 and 2: Overall Survival (OS) of CTX-8371

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1,Cycle = 2 weeks) until death (up to 2 years)

  8. Cohort 1 and 2: Maximum serum concentration (Cmax) of CTX-8371

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1,Cycle = 2 weeks) until treatment discontinuation

  9. Cohort 1 and 2: Time of maximum observed serum concentration (Tmax) of CTX-8371

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation

  10. Cohort 1 and 2: Trough serum concentration (Ctrough) of CTX-8371

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation

  11. Cohort 1 and 2: Area under the serum concentrations of CTX-8371 versus time curve (AUC) for CTX-8371

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1,Cycle = 2 weeks) until treatment discontinuation

  12. Cohort 1 and 2: Clearance (CL) of serum concentrations of CTX-8371

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation

  13. Cohort 1 and 2: Volume of distribution (Vd) of serum concentrations of CTX-8371

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation

  14. Cohort 1 and 2: Half-life (t1/2) of serum concentrations of CTX-8371

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation

  15. Cohort 1 and 2: Dose Response for CTX-8371

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation

  16. Cohort 1 and 2: Assess the immunogenicity of CTX-8371

    Screen for the presence and development of antibodies against CTX-8371

    Time frame: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until end of treatment visit

07

Study locations

11 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 33 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Nov 29, 2023
StartActual
Mar 19, 2024
Primary completionEst.
Dec 2026
CompletionEst.
May 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • University of Alabama · Birmingham, United States
  • Stanford Cancer Institute · Palo Alto, United States
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    2 sites added
    Show 2 added (2 United States)
    • University of Alabama · Birmingham, United States
    • Stanford Cancer Institute · Palo Alto, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06150664
Lead sponsor
Compass Therapeutics
Responsible party
Sponsor
First posted
Nov 29, 2023
Start date
Mar 19, 2024
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Natalie Warholic
Contact
CTX-8371-001@compasstherapeutics.com
617-500-8099

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion